VivoSeq
Metabolic & Endocrine

Gestational Diabetes

43

Pipeline Programs↗

25

Active Trials↗

20

Companies Involved↗

Gestational Diabetes is a moderately active landscape with 43 programs across 20 companies. The most active players are Hyundai Pharmaceutical Co., LTD., Amgen, Novartis. 11 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

34/100

Mech. Concentration

10/100

Completion Rate

76/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 2N

Neurim Pharmaceuticals Ltd.

1 program

Phase 2Z

Zydus Therapeutics Inc.

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical9

Misoprostol

Pfizer

Oxytocin

Retrophin

Norepinephrine

General Hospital of Ningxia Medical University

Ephedrine

Dr. Reddys Laboratories, SA

Human Recombined Insulin

K. Marcinkowski University of Medical Sciences

Phase 13

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Acetylcholine

Bausch Health Americas, Inc.

Intradermal Microdialysis

Anna Stanhewicz, PhD

Phase 29

Vildagliptin

Novartis

Melatonin

Neurim Pharmaceuticals Ltd.

Sitagliptin

Zydus Therapeutics Inc.

Insulin Lispro

Eli Lilly

Sliding Scale Insulin

Slotervaart Hospital

Phase 311

Semaglutide

Novo Nordisk

Metformin Hydrochloride

Boehringer Ingelheim

Empagliflozin

Boehringer Ingelheim

Acarbose

Bayer

Glibenclamide

Novo Nordisk

Approved11

Glyburide

Pfizer

Ergocalciferol

Alnylam Pharmaceuticals

Ursodiol

AbbVie

Metformin

EMD Serono

Liraglutide

Novo Nordisk

Analysis

Modality Breakdown

93%

Small molecule

53 of 57 classified programs — the dominant modality here.

7%ALL OTHERSPeptide47%

Small molecule leads; the ring shows all 57 classified programs, each share of the total. Modality classified for 100% of 58 pipeline programs.

Analysis

Trial Status

80

clinical trials

Completed31 · 39%
Recruiting16 · 20%
Unknown status14 · 18%
Withdrawn6 · 8%
Active, not recruiting4 · 5%
Not yet recruiting4 · 5%
Other5 · 6%

Clinical Trials

Trial Activity

80 trials

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
Recruiting·—·Phase 1·NCT05917587·30 enrolled
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes
Recruiting·TThomas Jefferson University·N/A·NCT06419777·430 enrolled
Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
Recruiting·GGeorge Washington University·Phase 2·NCT06948825·60 enrolled
The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy
Recruiting·—·Phase 1·NCT06911372·84 enrolled
Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes
Recruiting·JJaeb Center for Health Research·Phase 2/3·NCT06535789·30 enrolled
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
Recruiting·TThomas Jefferson University·N/A·NCT06419803·430 enrolled
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
Recruiting·—·Phase 1·NCT05946785·28 enrolled
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
Recruiting·—·Phase 4·NCT05482789·13 enrolled
Pregnancy and Postpartum Continuous Glucose Monitoring in Gestational Diabetes
Recruiting·IIcahn School of Medicine at Mount Sinai·N/A·NCT07174245·40 enrolled
The Impact of Myo-Inositol Supplementation on Glycemic Control and Oxidative Stress in Women With Gestational Diabetes Mellitus: A Randomized, Open-Label Pilot Study
Recruiting·MMedical University of Vienna·Preclinical·NCT07685015·40 enrolled
Effect of Home Ultrasound in Routine High-Risk Care of Patients With Gestational Diabetes Mellitus
Recruiting·WWolfson Medical Center·Preclinical·NCT07158970·90 enrolled
Poi for Mama: a Pilot to Improve Maternal Microbiome and Gestational Diabetes Risk
Recruiting·UUniversity of Hawaii·Preclinical·NCT07446205·50 enrolled
DECIDE: A Comparative Effectiveness Trial of Oral Metformin Versus Injectable Insulin for the Treatment of Gestational Diabetes
Recruiting·OOhio State University·Approved·NCT06445946·1,572 enrolled
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes Mellitus: A Multicenter Randomized Trial
Recruiting·IIndiana University·Preclinical·NCT05124808·828 enrolled
Preventing Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus With Immediate Postpartum Screening
Recruiting·UUniversity of Massachusetts, Worcester·Preclinical·NCT06457139·116 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)